Treatment of hepatitis C virus reinfection after liver transplantation

被引:6
作者
Encke, J
Kraus, T
Mehrabi, A
Stremmel, W
Sauer, P
机构
[1] Univ Heidelberg, Dept Internal Med 4, D-69120 Heidelberg, Germany
[2] Univ Heidelberg, Dept Gen Visceral & Transplantat Surg, Heidelberg, Germany
关键词
hepatitis C virus; reinfection; antiviral therapy; pegylated interferon; rebavirin;
D O I
10.1097/01.tp.0000186906.47521.d7
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Most liver transplant recipients become reinfected with hepatitis C virus after OLT followed by allograft dysfunction, transplant cirrhosis and graft failure in a significant proportion of patients. Both in the pre-emptive prophylactic setting and in the treatment setting sustained virological response rates are poor compared to the precirrhotic hepatitis state. Patients with significant hepatitis should be always treated before developing cirrhosis or even with early cirrhosis. After transplantation pegylated interferon in combination with ribavirin is the most successful treatment opportunity to date, however the best time point and treatment duration as well as doses for pegylated interferons and rebavirin have to be defined.
引用
收藏
页码:S125 / S127
页数:3
相关论文
共 29 条
[1]   THE NATURAL-HISTORY OF COMMUNITY-ACQUIRED HEPATITIS-C IN THE UNITED-STATES [J].
ALTER, MJ ;
MARGOLIS, HS ;
KRAWCZYNSKI, K ;
JUDSON, FN ;
MARES, A ;
ALEXANDER, WJ ;
HU, PY ;
MILLER, JK ;
GERBER, MA ;
SAMPLINER, RE ;
MEEKS, EL ;
BEACH, MJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 327 (27) :1899-1905
[2]   Recurrent hepatitis C genotype 1b following liver transplantation:: treatment with combination interferon-ribavirin therapy [J].
Berenguer, M ;
Prieto, M ;
Palau, A ;
Carrasco, D ;
Rayón, JM ;
Calvo, F ;
Berenguer, J .
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2004, 16 (11) :1207-1212
[3]  
Berenguer M, 2001, J HEPATOL, V35, P666, DOI 10.1016/S0168-8278(01)00179-9
[4]   Pilot study of the combination of interferon alfa and ribavirin as therapy of recurrent hepatitis C after liver transplantation [J].
Bizollon, T ;
Palazzo, U ;
Ducerf, C ;
Chevallier, M ;
Elliott, M ;
Baulieux, J ;
Pouyet, M ;
Trepo, C .
HEPATOLOGY, 1997, 26 (02) :500-504
[5]   Peginterferon alfa-2a for hepatitis C after liver transplantation: Two randomized, controlled trials [J].
Chalasani, N ;
Manzarbeitia, C ;
Ferenci, P ;
Vogel, W ;
Fontana, RJ ;
Voigt, M ;
Riely, C ;
Martin, P ;
Teperman, L ;
Jiao, J ;
Lopez-Talavera, JC .
HEPATOLOGY, 2005, 41 (02) :289-298
[6]   Treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alfa-2b and ribavirin combination [J].
Dumoriter, J ;
Scoazec, JY ;
Chevallier, P ;
Boillot, O .
JOURNAL OF HEPATOLOGY, 2004, 40 (04) :669-674
[7]   Rising incidence of hepatocellular carcinoma in the United States [J].
El-Serag, HB ;
Mason, AC .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 340 (10) :745-750
[8]   Combination of interferon alfa-2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C [J].
Firpi, RJ ;
Abdelmalek, ME ;
Soldevila-Pico, C ;
Reed, A ;
Hemming, A ;
Howard, R ;
Van der Werf, W ;
Lauwers, G ;
Liu, C ;
Crawford, JM ;
Davis, GL ;
Nelson, DR .
LIVER TRANSPLANTATION, 2002, 8 (11) :1000-1006
[9]   The association between hepatitis C infection and survival after orthotopic liver transplantation [J].
Forman, LM ;
Lewis, JD ;
Berlin, JA ;
Feldman, HI ;
Lucey, MR .
GASTROENTEROLOGY, 2002, 122 (04) :889-896
[10]   Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation [J].
Forns, X ;
García-Retortillo, M ;
Serrano, T ;
Feliu, A ;
Suarez, F ;
de la Mata, M ;
García-Valdecasas, JC ;
Navasa, M ;
Rimola, A ;
Rodés, J .
JOURNAL OF HEPATOLOGY, 2003, 39 (03) :389-396